News for CNS Pharmaceuticals Stock (CNSP)

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Accesswire • 01/30/24

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Accesswire • 01/18/24

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Accesswire • 01/17/24

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Accesswire • 12/18/23

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Accesswire • 12/06/23

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Accesswire • 11/22/23

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

Accesswire • 11/16/23

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Accesswire • 11/15/23

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

Accesswire • 10/19/23

Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hope

Accesswire • 10/16/23

CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

Accesswire • 10/11/23

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

Accesswire • 09/07/23

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Accesswire • 09/05/23

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Accesswire • 08/14/23

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

Accesswire • 08/14/23

CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Accesswire • 08/03/23

CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference

Accesswire • 07/27/23

CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series

Accesswire • 07/05/23

CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Accesswire • 06/14/23

CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Accesswire • 05/25/23

CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Accesswire • 05/15/23

Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors

Accesswire • 05/08/23

CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC

Accesswire • 05/03/23

CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study

Accesswire • 04/27/23

Essential Penny Stock Trading Tools: Maximizing Efficiency

PennyStocks • 04/21/23